Consolación Melguizo
- Biomaterials top 1%
- Nanoparticle-Based Drug Delivery 42
- Pharmaceutical Science top 1%
- Genetics top 2%
- Virus-based gene therapy research 10
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 8
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research 11
- Cancer Cells and Metastasis 10
-
- RNA Interference and Gene Delivery 21
-
- Cancer Research and Treatments 14
-
- Sarcoma Diagnosis and Treatment 14
- Co-authors
- José PradosRaúl OrtízAntonia AránegaLaura CabezaGloria PerazzoliPablo ÁlvarezJosé L. AriasJuan Manuel López‐Romero
- Journals
- Biomedicine & Pharmacotherapy (9 papers)International Journal of Molecular Sciences (8 papers)Cancers (6 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Consolación Melguizo
198 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 164
- Biomaterials 1.1k
- Pharmaceutical Science 287
- Genetics 368
- Cancer Research 499
- Oncology 807
Countries citing papers authored by Consolación Melguizo
This map shows the geographic impact of Consolación Melguizo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Consolación Melguizo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Consolación Melguizo more than expected).
Fields of papers citing papers by Consolación Melguizo
This network shows the impact of papers produced by Consolación Melguizo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Consolación Melguizo. The network helps show where Consolación Melguizo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Consolación Melguizo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2024 | 8 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 2 | |
| 8 | 2022 | 6 | |
| 9 | 2022 | 6 | |
| 10 | 2022 | 25 | |
| 11 | 2022 | 4 | |
| 12 | 2021 | 2 | |
| 13 | 2021 | 13 | |
| 14 | 2021 | 22 | |
| 15 | 2020 | 115 | |
| 16 | 2020 | 6 | |
| 17 | 2020 | 6 | |
| 18 | 2020 | 42 | |
| 19 | 2019 | 126 | |
| 20 | 2013 | 38 |
About Consolación Melguizo
Consolación Melguizo is a scholar working on Biomaterials, Biotechnology and Oncology, having authored 206 papers that have together received 4.4k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (42 papers), RNA Interference and Gene Delivery (21 papers), Cancer Research and Treatments (14 papers), Sarcoma Diagnosis and Treatment (14 papers), Pancreatic and Hepatic Oncology Research (11 papers), Cancer Cells and Metastasis (10 papers), Virus-based gene therapy research (10 papers) and Cancer Genomics and Diagnostics (8 papers). The work is most often cited by research in Biomaterials (1.1k citations), Pharmaceutical Science (287 citations) and Genetics (368 citations). Consolación Melguizo has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include José Prados, Raúl Ortíz, Antonia Aránega, Laura Cabeza, Gloria Perazzoli, Pablo Álvarez, José L. Arias, Juan Manuel López‐Romero, Cristina Jiménez‐Luna and Beatriz García-Pinel. Their work appears in journals such as Biomedicine & Pharmacotherapy, International Journal of Molecular Sciences, Cancers, Pharmaceutics and Marine Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.